EPCAM and carcinoma: Moreover, EPCAM-targeted antibodies and EPCAM-targeted drug delivery have been developed and tested for the treatment of carcinomas in vitro and in vivo, although evidence for the clinical efficacy and safety of EPCAM-targeted therapy in human cancer patients remains insufficient [1, 2].